| Display title | Chemistry:Deferiprone |
| Default sort key | Deferiprone |
| Page length (in bytes) | 11,492 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 805247 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>John Stpola |
| Date of page creation | 02:51, 6 February 2024 |
| Latest editor | imported>John Stpola |
| Date of latest edit | 02:51, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Deferiprone, sold under the brand name Ferriprox among others, is a medication that chelates iron and is used to treat iron overload in thalassaemia major. It was first approved and indicated for use in treating thalassaemia major in 1994 and had been licensed for use in the European Union for many... |
